MRI assessment of suppression of structural damage in patients with rheumatoid arthritis receiving rituximab: results from the randomised, placebo-controlled, double-blind RA-SCORE study.

Additionally, although treatment effects in the rituximab 500-mg and 1000-mg groups largely overlapped, in a few of the end points (particularly cartilage loss and joint-space narrowing), one or the other dosing arm did not reach statistical significance compared with placebo.

also in 111,027 other papers